BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 12108891)

  • 1. AIDS malignancies in the era of highly active antiretroviral therapy.
    Gates AE; Kaplan LD
    Oncology (Williston Park); 2002 May; 16(5):657-65; discussion 665, 668-70. PubMed ID: 12108891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AIDS malignancies in the era of highly active antiretroviral therapy.
    Gates AE; Kaplan LD
    Oncology (Williston Park); 2002 Apr; 16(4):441-51, 456, 459. PubMed ID: 12017534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Epidemiology of HIV-associated malignancies].
    Launay O; Guillevin L
    Bull Cancer; 2003 May; 90(5):387-92. PubMed ID: 12850760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The epidemiology of acquired immunodeficiency syndrome malignancies.
    Goedert JJ
    Semin Oncol; 2000 Aug; 27(4):390-401. PubMed ID: 10950365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic approaches to AIDS-related malignancies.
    Berretta M; Cinelli R; Martellotta F; Spina M; Vaccher E; Tirelli U
    Oncogene; 2003 Sep; 22(42):6646-59. PubMed ID: 14528290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [AIDS associated cancers in the era of highly active antiretroviral therapy (HAART)].
    Tserenpuntsag B; Kołacińska A; Jabłonowska E
    Przegl Epidemiol; 2007; 61(3):529-34. PubMed ID: 18069390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of highly active antiretroviral therapy on the incidence and outcomes of AIDS-defining cancers in Southern Alberta.
    Gingues S; Gill MJ
    HIV Med; 2006 Sep; 7(6):369-77. PubMed ID: 16903981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy.
    Cheung MC; Pantanowitz L; Dezube BJ
    Oncologist; 2005; 10(6):412-26. PubMed ID: 15967835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival.
    Diamond C; Taylor TH; Aboumrad T; Anton-Culver H
    Cancer; 2006 Jan; 106(1):128-35. PubMed ID: 16329140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Less cancer--or more--with HAART? Or, reflections on a late opus.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1998 Jun; 4(6):12-22. PubMed ID: 11365531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features and predictors of survival of AIDS-related non-Hodgkin's lymphoma in a population-based case series in Sydney, Australia.
    Robotin MC; Law MG; Milliken S; Goldstein D; Garsia RJ; Dolan GM; Kaldor JM; Grulich AE
    HIV Med; 2004 Sep; 5(5):377-84. PubMed ID: 15369514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AIDS and non-Hodgkin's lymphoma. Experience at an oncological center in Mexico.
    Cornejo-Juárez P; Volkow-Fernández P; Avilés-Salas A; Calderón-Flores E
    Rev Invest Clin; 2008; 60(5):375-81. PubMed ID: 19227434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Systemic HIV-non-Hodgkin lymphoma in the era of HAART. Natural history].
    Juzbasic S; Spina M; Vaccher E; Tirelli U
    Recenti Prog Med; 2001 Nov; 92(11):676-89. PubMed ID: 11765662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AIDS-related cancer in the era of highly active antiretroviral therapy (HAART): a model of the interplay of the immune system, virus, and cancer. "On the offensive--the Trojan Horse is being destroyed"--Part B: Malignant lymphoma.
    Cheung TW
    Cancer Invest; 2004; 22(5):787-98. PubMed ID: 15581059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-AIDS-defining cancers: should antiretroviral therapy be initiated earlier?
    Cinti SK; Gandhi T; Riddell J
    AIDS Read; 2008 Jan; 18(1):18-20, 26-32. PubMed ID: 18240449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
    Ives NJ; Gazzard BG; Easterbrook PJ
    J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV/AIDS: a systematic review.
    Cobucci RN; Lima PH; de Souza PC; Costa VV; Cornetta Mda C; Fernandes JV; Gonçalves AK
    J Infect Public Health; 2015; 8(1):1-10. PubMed ID: 25294086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults.
    International Collaboration on HIV and Cancer
    J Natl Cancer Inst; 2000 Nov; 92(22):1823-30. PubMed ID: 11078759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV infection and cancer in the era of highly active antiretroviral therapy (Review).
    Barbaro G; Barbarini G
    Oncol Rep; 2007 May; 17(5):1121-6. PubMed ID: 17390054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
    Clifford GM; Polesel J; Rickenbach M; Dal Maso L; Keiser O; Kofler A; Rapiti E; Levi F; Jundt G; Fisch T; Bordoni A; De Weck D; Franceschi S;
    J Natl Cancer Inst; 2005 Mar; 97(6):425-32. PubMed ID: 15770006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.